oral GPR17 remyelination program

Asset

Antagonism of GPR17 to stimulate oligodendrocyte differentiation and remyelination in multiple sclerosis.

Stage
Preclinical
Modality
Small molecule
Target
GPR17
1
Indication
0
Trials
1
Developer

Indications

1

In the full profile

  • Targets and what it contains1
  • Owner and partners1
  • Competitors5

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets